<SEC-DOCUMENT>0001213900-25-121102.txt : 20251212
<SEC-HEADER>0001213900-25-121102.hdr.sgml : 20251212
<ACCEPTANCE-DATETIME>20251212141011
ACCESSION NUMBER:		0001213900-25-121102
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20251212
FILED AS OF DATE:		20251212
DATE AS OF CHANGE:		20251212

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tiziana Life Sciences Ltd
		CENTRAL INDEX KEY:			0001723069
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			D0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38723
		FILM NUMBER:		251567552

	BUSINESS ADDRESS:	
		STREET 1:		3RD FLOOR, 11-12 ST. JAMES'S SQUARE
		CITY:			LONDON, ENGLAND
		STATE:			X0
		ZIP:			SW1Y 4LB
		BUSINESS PHONE:		0044(0) 207-495-2379

	MAIL ADDRESS:	
		STREET 1:		3RD FLOOR, 11-12 ST. JAMES'S SQUARE
		CITY:			LONDON, ENGLAND
		STATE:			X0
		ZIP:			SW1Y 4LB

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tiziana Life Sciences plc
		DATE OF NAME CHANGE:	20171116
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0269497-6k_tiziana.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM&nbsp;6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPORT
OF FOREIGN PRIVATE ISSUER</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PURSUANT
TO RULE 13a-16 OR 15d-16</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
2025</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commission
File Number:</B>&nbsp; <B>001-38723</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tiziana
Life Sciences LTD</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
Name of Registrant as Specified in Its Charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>9<SUP>th</SUP>&nbsp;Floor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>107
Cheapside</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>London
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><B>EC2V
6DN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of registrant&rsquo;s principal executive office)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form&nbsp;20-F or Form&nbsp;40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;20-F&nbsp;&#9746;&nbsp;Form&nbsp;40-F&nbsp;&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
CONTAINED IN THIS REPORT ON FORM&nbsp;6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 12, 2025, Tiziana Life Sciences LTD (the &ldquo;<U>Company</U>&rdquo;) issued this 6K announcing, that enrolment has begun in
its Phase 2 randomized, placebo-controlled early Alzheimer&rsquo;s clinical trial and plans to dose the first patient next week. The
Phase 2 clinical trial will evaluate intranasal foralumab both as monotherapy and in combination with an FDA approved anti-amyloid therapy,
lecanemab or donanemab, in patients with early Alzheimer&rsquo;s disease (AD). Baseline clinical assessments, cognitive testing, TSPO-PET
imaging, and fluid biomarkers have been completed in the first participants screened in the trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Announcement is furnished herewith as Exhibit 99.1 to this Report on Form&nbsp;6-K. The information in the attached Exhibits 99.1 is
being furnished and shall not be deemed &ldquo;filed&rdquo; for the purposes of Section&nbsp;18 of the Securities Exchange Act of 1934,
or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company
under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall
be expressly set forth by specific reference in such a filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TIZIANA LIFE SCIENCES LTD</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: December 12, 2025</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Keeren Shah</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keeren
Shah</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT&nbsp;INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 90%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea026949701ex99-1_tiziana.htm">Tiziana Life Sciences LTD Press Release, dated December 12, 2025</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT>&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea026949701ex99-1_tiziana.htm
<DESCRIPTION>TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED DECEMBER 12, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit 99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_001.jpg" ALT="" STYLE="height: 54px; width: 236px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tiziana
Life Sciences to Dose First Patient in Phase 2 Alzheimer&rsquo;s Trial</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>First
                                            Patient Expected to be Dosed Next Week with Intranasal Foralumab</B></FONT></TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
                                                                                                                                 </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PET
                                            Scan Shows Presence of Untreated Neuroinflammation in Alzheimer&rsquo;s Patient on Leqembi<SUP>&reg;</SUP>&nbsp;(Lecanemab)
                                            Anti-Amyloid Therapy</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BOSTON,
MA, December 12, 2025</B> &ndash; Tiziana Life Sciences, Ltd. (Nasdaq: TLSA)
(&ldquo;Tiziana&rdquo; or the &ldquo;Company&rdquo;), a biotechnology company developing breakthrough immunomodulation therapies with
its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, announces that enrolment has begun
in its Phase 2 randomized, placebo-controlled early Alzheimer&rsquo;s clinical trial and plans to dose the first patient next week.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Phase 2 clinical trial will evaluate intranasal foralumab both as monotherapy and in combination with an FDA approved anti-amyloid therapy,
lecanemab or donanemab, in patients with early Alzheimer&rsquo;s disease (AD). Baseline clinical assessments, cognitive testing, TSPO-PET
imaging, and fluid biomarkers have been completed in the first participants screened in the trial.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical trial launch is supported by new TSPO-PET imaging evidence demonstrating persistent and widespread microglial activation in
an Alzheimer&rsquo;s patient despite treatment with lecanemab, confirming that neuroinflammation remains present even after amyloid plaque
reduction. Lecanemab, marketed by Eisai and Biogen as Leqembi&reg;, is one of the two FDA-approved anti-amyloid therapies for treating
early Alzheimer&rsquo;s and is proven to reduce beta-amyloid plaques.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
1.</B> TSPO-PET scan of an Alzheimer&rsquo;s patient treated with lecanemab demonstrating persistent and widespread microglial activation
throughout the brain.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_002.jpg" ALT="" STYLE="height: 249px; width: 624px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Howard Weiner, Chairman of Tiziana&rsquo;s Scientific Advisory Board and co-director of the Ann Romney Center for Neurologic Diseases
at Brigham and Women&rsquo;s Hospital, a founding member of Mass General Brigham, stated, &ldquo;This PET finding is a critical insight:
clearing amyloid does not turn off the brain&rsquo;s inflammatory response. We believe intranasal foralumab directly addresses this residual
neuroinflammation by inducing regulatory T cells to migrate to the brain and calm activated microglia &mdash; a mechanism we have already
shown reduces microglial activation in secondary progressive multiple sclerosis.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
2.</B> TSPO-PET scans from intranasal foralumab-treated MS patients showing marked reduction in microglial activation over a 6-month
treatment period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex99-1_003.jpg" ALT="" STYLE="height: 299px; width: 624px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Phase
2 Trial Design and Rationale</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
study will evaluate whether intranasal foralumab:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
                                            a monotherapy, reduces microglial activation and slows cognitive decline by suppressing neuroinflammation.</FONT></TD></TR><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
                                                                                                                                                                       </TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
                                            combination with lecanemab or donanemab will provide additive or synergistic benefit by simultaneously
                                            targeting amyloid pathology and persistent microglial inflammation.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;With
enrolment now underway and baseline neuroimaging and biomarkers secured, we are on the verge of testing a fundamentally new approach
to Alzheimer&rsquo;s &mdash; one that treats the chronic brain inflammation that is associated with ongoing neurodegeneration. We expect
the first patients to begin dosing within days,&rdquo; said Ivor Elrifi, Chief Executive Officer of Tiziana Life Sciences. &ldquo;This
milestone marks an important step toward testing whether immune modulation alone, or in combination with amyloid removal, can achieve
disease modification. The PET evidence of inflammation in AD with or without anti-amyloid treatment provides a clear biological rationale
for this innovative strategy.&rdquo;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Intranasal
foralumab is a fully human anti-CD3 monoclonal antibody designed to induce Tregs and suppress pathological neuroinflammation, positioning
it as a potential first-in-class therapy to address the inflammatory component of Alzheimer&rsquo;s disease that remains active even
after amyloid clearance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
the Phase 2 Trial</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Phase 2 study is designed to evaluate the safety, tolerability, and efficacy of intranasal foralumab as both a monotherapy and in combination
with lecanemab or donanemab in early/mild AD. Key endpoints will include measures of neuroinflammation (via TSPO-PET imaging), cognitive
function, and biomarker changes related to amyloid and tau pathology. Results from this trial will inform future development and may
establish a new paradigm for treating AD by targeting neuroinflammation alone or in combination with anti-amyloid therapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Foralumab</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foralumab,
a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed
intranasally. At present, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label
intermediate sized Expanded Access (EA) Program (NCT06802328) with either
an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied
in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive
multiple sclerosis (NCT06292923).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foralumab
is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab
represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.<SUP>1,2</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1 </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://www.pnas.org/doi/10.1073/pnas.2220272120</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">2 <FONT STYLE="font-size: 10pt"></FONT></FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://www.pnas.org/doi/10.1073/pnas.2309221120</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
Tiziana Life Sciences</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tiziana
Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies
to enable alternative routes of immunotherapy. Tiziana&rsquo;s innovative intranasal approach has the potential to provide an improvement
in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana&rsquo;s lead candidate, intranasal foralumab,
which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical
response in patients in studies to date. Tiziana&rsquo;s technology for alternative routes of immunotherapy has been patented with several
applications pending and is expected to allow for broad pipeline applications.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain
statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather
are based on the Company&rsquo;s current expectations, estimates, and projections about its industry, its beliefs, and assumptions. Words such
as &lsquo;anticipates,&rsquo; &lsquo;expects,&rsquo; &lsquo;intends,&rsquo; &lsquo;plans,&rsquo; &lsquo;believes,&rsquo; &lsquo;seeks,&rsquo; &lsquo;estimates,&rsquo; and similar expressions are intended to identify forward-looking
statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and
other factors, some of which are beyond the Company&rsquo;s control, are difficult to predict, and could cause actual results to differ materially
from those expressed or forecasted in the forward-looking statements. The Company cautions security holders and prospective security
holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of
this announcement. Actual results may differ materially from those indicated by such forward-looking statements as a result of various
important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled
&lsquo;Risk Factors&rsquo; in Tiziana&rsquo;s Annual Report on Form 20-F for the year ended December 31, 2024, and other periodic reports
filed with the Securities and Exchange Commission. The forward-looking statements made in this announcement relate only to events as
of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates
to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement
except as required by law or by any appropriate regulatory authority.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
further inquiries:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tiziana
Life Sciences Ltd</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
Spencer, Business Development, and Investor Relations<BR>
+44 (0) 207 495 2379<BR>
email:&nbsp;info@tizianalifesciences.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->-</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1"  V .P# 2(  A$! Q$!_\0
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MB- O\J6>WANHS'<11RQGG;(H8?D:2T8R64+N<LT:DGU.*\Y\$:K;:HEA+?\
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A^$KOQ0+G6M/O%T:UO9C)':VQ) PJJ6;H-Q().*** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex99-1_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #Y G # 2(  A$! Q$!_\0
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M%6E!WBU=>C_JQ\FE*+<);K\>S^:"BBBLAA1110 4444 %%%% !1110 4444
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M85RU<=>DZ51P_KR/G8\UK2W6C]4%%%%8E!1110 4444 %%%% !1110 4444
M;_@Y=WB.WSD#/;K7U/9!C\-6V8!\HD\<=<]J^3O#MX++6H)2!@G&3VKZC\$W
M']J^$+FP:0"0 C(/;'%1C;_4U)=)/\8Z?D=.#:4Y-]'%_)-IGD4K6\C9D:0X
M;D9XK6M)+">V%M;),KDX9QTQ5>70I8[NY@E4Y1B5]ZLI;PZ9IYF9V#2#H.QK
MZ[&5\/6IPC3J2<KKE2>FJNO7YGW"MNC)U"T^P7IB2;(4 \-TI\D[75Q!%*0%
M4<LW7%1F)IY8Y'.=QSN')J0VCO(D*C=O. QZ_2O;C"]&$ZLKRBG[WYLY)UX0
MJ>QW;+-G.89UEBD#20/E,]Q74?\ "2Q7L;L2  #F,CD&N1DMUM+I2'PZM\V#
M5D>2)<A0">,KTKQ,RRC!9K&%:JO>2LG]WY[H\K$XNGEU7EFKQEJO)]OF0W<B
M/.)T=?*SD@G#=:Z.ZOQ)IJ%)Q@+QS7,QVCN[SPHK1$9Q_/\ K4<,SRRJ-JA"
M""HZ5>)RFCBW3]]-TWV\MGYZ;GHKEHQ=2%.U_>>V_GYD%P\MU,S8)V\9Z]ZE
M%@SQ^<'&.N.Y^E7YE6.%MB[4..4_6M*WTI)75E),1& *Z\=F,,%3C]E>F]NG
MJ1@,7]<C.HU97LNY@F%$"M;D/QT858TV=[$D21@J1G..E7YM(N(9I#;E<'G!
M/>JFH6M_%!^^B.,XP@S4+'8+'0]G*:]ZW6S,:4,;2J\EU*%]V];>?H;4 BNH
MQ*R*RGG'6M#PC;(GB%[O B0#OQT_^OBLVVG5-*1X(B'Q@AAC%=)%:I9^&)[W
MK*4.WCIVK\[S'$5*5.=&%USOD2;\U?\ 3UZ'HUY+D<7UT. ^(,UM<:GJ$F1Y
M+8 .>"1G^M>-SN))"0 !Z"NY\:RNU@K;CN+ M]3UK@J]K%4_8<F'7V$EZV/@
M745:O4JK:]E\M/T"MKP_KT&A&Y:31--U.24*$^WQF18\'G"@CK6+17&:&[XH
M\3/XFU 7/V"UL(E4 6]J"(\X +8)ZD #\!4/AFV6ZUZWC;/!W#%9%;/A>=+?
M78&D.,_*/J:VP]O:QOM=&=;X&>B0Q"2Z;S"=O)Y^M$J/;29BVD2=,5O+I1N]
M.%U;XWQ@[E)P2/QK'F "CGE.%SV^M?;8;,J6*YX1:]UM-/H^E_4^BKXF>$QD
M*DG:BTE?MH4GM72#SMXR3@C/-+9R1QR;9/7H>@-6H)) &?RXW '(8X%=KH'@
M!M<L$OI$$8;HHXS4XK-HX*%\2KJ6W+9OTMY=ST:F(PN)H-QG[KTNCDIYXX%!
M"E@?X^]4B3=3".-MD>/7CUKTF[\!M:E$=<J/X>HQG_)JE;Z!%/+Y4<"*Z'!.
MW@U\W/C+ 4[QA!J2W;T:^3_0X<OR_"T?WJ:;74Y'2)8+9'\U-V3@;@,9K.N$
M?[?*T46!NZ8Z5TGB/1FTFX!+!0,' /%9D:337GEQ[0S G&<8'O7MY?BL/5A+
M'Q=U):WV5CLQF,K4ZD(T(<W-U[?TC3T_5Y+2&-)U5!U#+V^OY5:O?%;F%O*=
M"^.OK7.R+(UT8KA /*Z@=_>ENK> 1A@F.<C8M<M7AK*\176(E%-O735=_P 3
MDAF7)45#$+]X^VROL1&X,TA:39YLIR=_05>TVRDU!FB=XA%T)]1[4EAIMG=.
M)DE+XZJ_>MQ(X+2W9E4*/;O6>:9K&DO8X5.,[)+3;[SO6 H.?M:D4Y]S+N;*
MWCO1;1F5>/O*>#5Z#3+66U9)  P'#=,U';VSW4V]W.2.A/05CWL5ZL\PAGE=
M%]*\Z$:F)MAXU^6<4FWKO?\ 7L>@VRC>P117:I&X= >=IKJ)],ANM-C9(SM"
M<,!STKF8K8/*F[>%'WF*]*[RQ,2Z/-("2JIQFNCB?%U,'&@Z4FY1:7K=I=.I
ME&?-'FMN<1(,Z< <E@< 'V/_ .NO/?%RXU6,YSF(?S->CM'YA6,DE6;@@].I
MKSWQE(IU&% N"L0Y]J];.9J6&Y7O=,^.KI>R4HK1U)_D<W1117QYR!1110!T
M'@B58?&.G-)(RQLY5@MOYYD!!&S9D;MW3KWKI/B:M@/LB_:M475%9WEM+[3A
M;;4<E@PP3CL .>!VQ7+^$9I8/$UH\5W9VK'<IFO)#'$H*D'+ $KUX(Y!Q6_\
M2Q>FXTJ6XFTR6VEMV:"33[I[A&.[#L6<9R6&<#@4 <)1110 5]%_!;3HOM"$
MP*/*B#!O0G!_/FOG2OI#X)W"%H\,2SP8QG(&,5H]</47I]W,KFM!I5'_ (96
M^Y?I<Z7XEZNL#0VP;)7G;ZUY_J,MA*L4LP!<#[H/K6Y\1V^T^))E(W"-.![\
M_P#UJXVPTZ:YFCD;[@/6O7RO T5A(XVI4<6W)_FK?@?68"4535-+5)7^>HKB
MU&V1E9!GE>F:$U9XSM^^J<(3U%6=6C_TH,@5E5.1GI4""UN=+9<!+F,9!_O5
M]!"=&KAH2J1<DWZN-_Q.KE?M7+7;OH07DEQ.\4LAW;NGM5JPTQ;FY3"MY0'S
MMG'/M3+&%97BBC^>63A2?X17I.FZ/!96L<0;+..2.Y]?\^]>+Q)G]/),-&A!
M?O)72MI9=_\ +S.15W4J<S345MY]_DCB=6T*33K?SE+-"_WCG)!]:EL-#^W6
M#R.I8.0<]QQ5WQ;%<6<J6TC%T W!#T-:/A"^;^S);:(!GC.06%>!BLTS"EDD
M,:I*4[K75>[=I7\[[G+3EAUC9RIK]YRKT:O_ %<X:]MI+29[=1AH^01P<>];
MU@%CLXF0B0MU8UHZSX8O-25[N  RC.ZN0@N)[!Y;=BJ..&5AG)KZ##8JGGV!
MA[&:=2-N9?@_EV/1C)4[ZZ?DR[XA6431,QW18X /?Z5';6IGLI+I@I91\J ]
MJHM=W$Y4$;T7@+C(IUM=26<@!&T$U[4<)B:6!C0BUS1[=5?]2TX.KY]-?T+T
MVES3>5/&H*L,E?2NM^'.O3P:A)HI"B)P?SK!-Q)<)NC=0VW< *J:6+K2]>M;
MK!!WY.*\"LI8O"5:-=JZ3<>]U=_E=%5Z?M:;@R#XG>'OLANXCP.9D"UXQ7T;
M\3R9W2Z3DFW8$"OG1_OMQCGI7ATJRKX.C5O=N-K_ .%V7X6/BL6K8AZ;I-^N
MJ?Y#:***1@%%%% !1110 4444 %%%% !1110 5[]\'=7EB:W2Y)V3+ACZ^_Z
M5X#7J7@._1;.U*-B1&*,0.G?^E;PI>VI5:2W<6UZK5?D;X57Q,(O:5U]Z_S1
MZ_XXTM+"07]NX GSP!W]:\WN;:^V.9X]ZL,*"<X->L6EQ!XCTP6DK#S8AD#-
M>>:CJ$EOJ,]L(L^5)M)!R*Y,@QE>4Y4J5+5:Z]%V771_@T?58:M[*FX5G9QZ
MOMT,&U#QI]G56$C-@\=.?_K5TD/ARX?RKA)VFD4[MI'>H[S4K=]HM@/-0@.,
M?U_PI]QXF>VMO)M0$=AD2<?E7LYCC,YQ4*?U6G[.]U+FM:VSOY=K:F-2>$P]
MZTFK[W=KD$VD+OFEF0-,P. >QJF^E75G;Q7$L3B+U49'T_\ KTD%SJ=[.A$A
MDDE;IBO;] L3/X<C@O[=02FTYQR,?_KJ)XS&8"4*-249WU:3>B2TMV3?6W0X
M\PGAL9AH5&VXM]-'H>,:!974PFF6!C;LIQ\O J5=/@AN98!;MYG=,$ 5[O9Z
M;9V$7E6\"HO7 &?\]ZA;0=.>Y,[0#S#SG-<.)QV+J59U8I+FZ)M;;7?7\#2&
M;TX^[RNRV/*-'\"7&J*SO*Z1#J@48_SBJ^O0_P!@*EK YSU"=CBO;(XH;9-J
MA46N#^(&DZ;_ &>;X!//&2"&Z\\]\>M<SK8BK7I3QM1S@GK'2VNBMITZO<RP
MV.<JKC"*5]M.OF>;0ZY<B<330*47J=W3_P"OQ5J\U^\NY=RVZH@'&6Z_YS6&
ML2.JRLY7=TP/S%2E?LR%99AACCI7V#R/!2JQJ2H+F2LM79?*YY4<ZS#FY'27
M-=_AY%HZW,55'B0$GYAGIS71:AXEM/\ A&!91C#NN H'?_\ 77#B5=S"./>Q
M&5;Z5-<7)BMM[\RXY _6LL5P_A)N%:HN10ES63W]?N1U2S/%4:?M,=!+LEN<
MWXU(32XU)&]RIZ_TK@:W/$<U]<7(ENHRD9X0?SK#KQ<=65:O*:5CP\,O=<N[
M;^\****XSI"G1R/%(LB,593D$=J;10!Z1X5\;SF06LDA1V&W&>'_ $K=\B:Z
M,K;#O9]V ">*\ALYVMKR&93@JX-?3?PW&D7FASQW^QIV);DG)!'6O3IYA#"X
M>I7E!.3LF]M-=WY>?EJ;0YZ]*>%G)\EDUU>CZ>1Q_ANQ@O-8@L[J4B+<&D/7
M( Z9_"OH"R-E;V\<%M)&%' 4$?RKYYUR1;3495L3LA\Q\8/^T2.OMC]*SM-U
MFZTZZ%U)<LLH(^;L>>]=&+PZQ$U4C*RY5RIK1/??I?T.18K#4']2=XJ+M?>[
M[O\ IGU!+&LT15@,$5Y5X@UQ?#=W*@57D).T9QCI6<_Q.NGACCBN2&V[1P/F
M_P \5Q]X;_6[Z::8EI,;L$UY%+A^&.K1K8Z/+3A>^JN^VS^=SW\I=*<I*,U+
MR-"XUQ]<NXFO$!#$C!/3%:,?V"T/GR*(CG *\UC:5I D29+O]VVWY">U6;6*
MU@M95O9P\<;?)7HYA1P=W0PSDHPLN6-]>;JNC\[GT<$XJS+<^BWE[JCW5JA9
M"F<UD2"6-W1UP\9(.[(S7L7@LPW&FB>V12!C(QUK"^*-@(8(+R" AV/[QAV'
M.:X\GSC$MPP]:-HI\BZ-6NE?H]O*WF?(YK0AB*TVKJ:6GRUV/-H2EKY]P !\
MORX[&K>CWXNM]O>CY,%@QJ)HC)&RM&2W5@/\_6J%U=E083#M8=^]?95L%2QD
M)1D_?=M;ZJVS1WY7C,74HP]I"ZVOMIT?GYFYI4MQ=7\I20FWCR!GCUK3"6\4
MTI5@"W4<9)KF]&U*>Q=0/G1VQM'6M:STTW]]/<R0M$!RJ[NIKY+-L)]7KSG7
MER4U%6:MKJMUIK?4^@4E+5,UX=*MYM/=G(5>21BL/4-53:;"S0+$HQ(X/:K4
MIN(8I TWRD' Q7/[D2-<@EYL%CBEDV7*I4GB,34YXIWBNEW^=CR<VQWU/#N?
M5Z+U)DP;V/RP %CR03CMBO,_%C[M9*]T0*<>O-=[*Q>[?R\[3@';7F>LL7UB
M[).?WA[U[N>)QA&[WM^"_P"">+BFXT*%)O6SD_GH4:***^5.$**** -WP;!+
M<^*[&*&*RE9F.5O8/.BP 2<IU;@' ').,5O_ !"DEM[BW7[+I1M;FWQ ]OIC
M6;* ^2?+;E3GC/<5R6B7=I8:Q;7=];SSV\3[FCMY_)?/8JX!P0<'\*V?&FK:
M/K=Q97VFMJ1N'B(NEU"Z:X=6#$* Y R-O/XT <O1110 5[#\'-0%I>0R%\*H
M9&/U.<5X]77^ [Y+6_D5@>/W@Y]*VI4W64J*WFFEZVT_%(UH24:T&]KV^3T_
M4]K\4V]MJ>I221.R2@GYOK_G]*Y:XN3IT,5NF"RGEO6I&\0"YU'<P\N(\%O6
MHM4CM=ZS-)N&>@-=>68/$X6-/"XV[5KI;ZN]U?Y[=#[BE3C';T^XRG8W<I.[
M$C-R,\4U;-S<F-&X4<G/%6H-*$L[AI=B,I96SUIZNMK"%*9QU8?S_G7V-+$T
MX75.6B2TMW_RML>9G./^IT.9+5Z>G](DT=574W# EE'! Z5O1>+%M6> 1/(R
M'*D^M<=%KJQW7[K"S9V\KZ]C]/ZU9#27!7;N"DEL=^><U\_C\!@LTKNIB%SQ
MLK*[336_HOF>+/B.A##1Y(WGVV^9JZK?W^MW8N9E6)XUPBCTJ#3+R_TN<M#)
M^\?@H>*9$0Q\M?F4=U.<'_"H-15T\N8,.#UZ5[M+!8:6'^HNFO9VMRM?/K]Y
MEA,PK5:_+)*,GIMMIHO1G5)XUF0+;-&T;YY/&*YW5C;75W]IC_>/G]X .M0W
M#QMM9D#'&5/X4QQ';P&2)F&1RH/'XUY&#R?!9=6=;">X^JU[[>G9'73S_"*#
MC6BU*VMNY)#) (U>/*KG:%QDYH-K]IDN)-F\IP!4-M)O?!50JY(V]#]/UK8T
M2\@6::"=-K2_,"3STKOQ^+JPPL\11BY6MIUM?4PR*O'$8F=:/P[*^Y7TMH_L
MG[V,JX/!QUJP]R(9D<2!H@>A%01W0BN)H @<*Q(&*35X8WLDF8>6V?NUXLJ<
M:F)7M$TI_/=?>?9]1?&NIL; 31LI"0'.*\.9BS%CU)S7?^+KLKHB!)"&E8*1
MGD@9KS^O-Q&&C@XPPD-H+\VW^I\/CIJ>+J-;*R^[_@L****Y#E"BNS\%:YJN
MEV&H6WA^S>ZU:XDC8*M@MR?*7=NX(..2.W_ULSQ+XLUOQ$8H-8\C?:LP"I:1
MPLIX!!VJ/3H: .?HHHH **** "BBB@ HHHH *ZCP7>O'J#6A/[N3GC@@_6N7
MK3\/RF+68,'&3@_E71AJCIUHR7<QKW5-R6ZU^X]FT^_N]'E$T$F%0<@\DUD7
M6H->R37,K#S9'SCI4L[R"**-!DOQ@\G_ "*ZKPAH$JR[I;,3JYPQ:/=BOHLR
MK8/+J<L8X+VDELK)M?UY'NT:4\?@7]8E9.VNE]/4YFVL9Y8#)';22+C+.O'Z
M5'#L R5(4DC##)':O;[;PQ&(YH]BK%(,8'!KB=9^'E[89DLV$D."=N"6SG/\
MOI7D99Q![=R^MT_9K[+U?E[WZ:6]#SZN782=-4Z#]]6UD]]/N.7TO6)-*UNV
MEB08!(R5!!']*[@_$"_NKK[-90D%!R=HQUKS:4O 490"R/@@\Y)XX->B>!M(
MG@D-PZHS2@\,.<&EQ/&A14<2_CDN6*3>KOO9;I(]; ^Q>#4JD%>-U\[FK_PD
M^H,8U2=$DXWJ5R?_ *U=18:W:3Q*LDZ^>1\PZ5Y]XPTRYMYII;6)DW L& P,
MUPVG:I/%K4<AFD23."';BOFLIR[%5Z,\13JI\B?NRO>^_36VFC.FIA*-:$>1
M6OV7YGLGCMI9-$,-I*R3$[@4)''3M]:\8U.VU46X-W-*R*=HW,3D_G7OMC"N
MI:/&;A49BO#5R?BFQ?3M&N(GCB<,<H0N3^)K7 YQB<'6C/V:E3J.+O;5;*VO
MYF> KQI_N+>\FSRU$94A@6,^;(0H'<'^E>I:9\,M/ET@+J.Z2Y?YMP8C!^G:
MN/T;2"C"ZF >5?\ 5HH_/C\*]HTY773K<29#[1NSZU[F89XL5C'0PTGRP6K3
MM[WEZ)_?Z'%5I2PD543M.3U_R7ZG$GX7V*VC0QL%)S@EC7F_B'P[<:+?M#=*
M_DE?DD/ ZG&?R_2OHC/TSSQFL_5]'M=9L);:>,'<I"L>"I]<UA@\35PT[N3G
M%[J3;^:OL_P.:>(CB8NEBES1?WKS1\LZ[HD,]L\LQ^X"0P. />O.&&&(!S@]
M:]>\<6<VC6US8RNK>6C*".>Y%>05U9@Z4IJ5'9JYXN%I.C.I2OI%V"BBBO..
MX**** 'Q#,R#KEA7K^FWKZ45%N&YC"X!_"O);&3R;Z&0!3AQ]X<5[!IMLUX^
MU &S$"._(KV,N5#V55XA7C97OVNCKRR5L?%?W9??H4;O4XK<2M=2KN<Y^;H/
M85Q7B75UNWC2WDRHY)4\?2MGQAIW^CO<ESN7J,]_ZUP7+''4FC,<14YO9627
M2W;I^!X[ISK8F5:O\:;37]>18%Y.9482LI4C!!KTC1KR>;24D+9<*",9KSL:
M;<.T82)\L,]*]'\/VLEG:6L3 M(?DPG.<U65<RK-R5U;7T-:<Y1Q-)X=7E?9
M=NIT$NC7$NF)>0K*N1D9R<U7@\/ZB\.9;6=@_((Y_&O;K3P]!-X8MK4J$;RA
MS[X]:OZ=I MK80SK&P7A2!S7CT\_S.G+DIPBTVVFT]%T5T?75<T@XM=4^]CQ
M_0O$6H^"Y'M)SF)@&5=HSFO5-*UJR\260CGB&9%^Z^#G-9OBKPU:75L9(U7S
MEZ9' J+P?X=DLK@3R[MJ#Y?2O+Q6/C6G&*CRUV_>2NXR3W:7V?-]S"L\/6HN
MNW:73O\ \$JZKX!>.>:ZLG383GRR"2>:X?4=#234QYT;(VT9)_3BO>21CD\=
M#FO._&FMZ6[_ &. )]I5A\ZD?T^@ZUUJ>)HU5.A)WLUUOZW\O,K+\=5G)4Y*
M_F<'9:3]GN/,9E,:\*H'3G-;T*QI<'R\LNSH#6+!JI228.F3&<'TIM_XCEOV
M\JTM#&V/[N,?E6N/R_-<?57M%[K5N:Z44M-7U/6C5IN4J<&M-_+J)>7KJSQR
MP,A?*ID]:SX-$NK^W,D:E54 %L=?85K:%X2U+6+P22>:J*1S+G!.?Y5J^+M3
MBT6.+347$FWYVC&,FO0EC)X6I# Y:E.K)ZM7<59:VN^WF<=2G#$8B$I:J.J7
M9]W^B.#OK=])@DDE(4*I8LWY5Y++(TLKR,<LQ))KTWQG+YFCRL"V-@7#$'G-
M>7UT9E6JU.15=[7?S?\ P#P\SGS8R2_E27Z_J%%%%>2< 4444 %%%% !1110
M 5IZ#>?8M7AD.-K':V?0UF4H.""*N$W"2DMT3*/,FCU@L1$\?&U3G\*OP!-4
MMC L01U^ZV:YK1+X:MIR88?:(1M=?7WKI-(G^SP2[XR64@@"ONL765?"1Q-'
MXE:WDSZ[*\1"M2NG[W5=GU_S^8R82(RVLY93&F%*_P 5 \QH%6>'Y'&%?/4U
MN+9I>,MTX*DCA:I:S>^3&+78/F&0QXQS7E83,'6JQP].";?Q>6]VOS.C'X2E
MBZ+A47>WDS-73H< E<>A)_ XXI8XYF98H#LASC?CK4LP2XM"ZN>!S3(=7<68
MMO)#=ACO7K5*,Z,.:A%.5[/I;S/F\CRK#QG*I-7DM+-;?>-?RH[DQ)(,Q+G>
M.^*NZ?+'>W";X=Z+RWI4)A@D@FG:W=' P/K5C28[I;6,)&%C<Y9^]<&)Q*6$
MFD]=KMVU:NVK'U%3"4IU8U6O>CL)>6IMK=IT;;%N($1]#[UES?9I#@.Q)&<Y
M/%=1?69N8Q"3M!')([5R]Q9&*^:* LR X+?TI9/B:>-ING6=Y;_+S?\ F>9C
M\IP5?][55K;VT)8E2U@WX#,^0".3BG06-U)/$ZMAV.>>PJ:2&)42W"<.VS.<
MXKKSIT LH0J_-$O+=JY\YSBEE4*=)+X[K;\7\S'(J%&E1<J:W>C?5&7%8QVD
MXG1=[D#<"<U3UFZ 7RE57+COVJ]J&L6UJWV:-"9&'ZUR>J:AY4<U[=)M6-?E
M'^U7EY3A:]>2QN+BU%+1OJNFAZV*QE/#4Y5)[I;=7V_$XKQC=>9?Q6H  A0
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M3UKHR*O2I8J=7E]U1M&W5MZV>VGWG7E5%QA*<]WW.'\;7KR6**&(61Q\I/4
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MV/XOU%4K3JKD>D%M'_/NPHHHKQ2 HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "C)]:** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
G **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>ex99-1_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $K G # 2(  A$! Q$!_\0
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M1]OO/^?N?_OX?\:KT4@+'V^\_P"?N?\ [^'_ !H^WWG_ #]S_P#?P_XU7HH
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M.J-]#-8R2-.@^10ZE#\L@;D,OJ"/ITK:][1Z[V^[]=/\C.+NK_UM?_@F6O\
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MKKLQEC:RB"")E?SF 3;YSA<Y[?-CU/TS5R731:1S3ZA)+;01LBEA^_\ ,+=
MH)P5QR34%C<O+=28=E:V(=3L[]1CVYZ_6J]QXSTNQO[D_;I1<[@K1I&"" .
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MQ_E_,1T5G+/!+!8W%L0S("&5D&6!^O7^==1'XBN;.-;9M.-LD2* /,4'>O\
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M3IO#<,-_;7$&Z;2Y,,,-DC/;(ZBN2C*A4JRI.-F]5?2]ELM5KY:76QIB*]?
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MM.ZM=/=+RO?NK7%OY;%C"=-M;T1E?F:5,%O?!/UJ&TACO;"[D6"ZDEAR!&B
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M?KINOQW\B*E-TI\BL[>;NM=G=+5*US=L+B\M=->\N[N+8)1#*(TR[L<\%3P
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M;*@Z.P(_^OS7I6M:KX;MPL;P:9(H#,##:L?/)[#^Z@/XUB76C:/:_9?$-N\
ML[E#(FULB)QP5(/((/&*')NUP.;^(6G#3/&VHPA74-(9"'.2"W)'ZUS%;/BC
M4TUG79KZ,NR/A0SGEMHQFL:I&=S)<SV?PQTQ5&UH[]I020<[EXP/H*Z70[F-
MO#\,$$'FB14;)]0"<?KVKG_$>QO FD20C:A*%1^!%'AG59+30!./WKP285,
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ME%91TPY#8SD\A^TFQ77M"P?^763J!_>%>OM\/[5Q<+)KNNR1W+A[B-KL;92
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MQ;V%G*CH9U>-.#Q@QG'))Y)(/>L;4_']M=7;'5;&&;3(TVS IF1<=2AXP<D
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MO3M]UHE3C)WMUOIZ6_X?N_N/2_"\5O\ \(E.DPED:_+73A#A#$C%BK8_BSC
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M.@TC7E\/W3W2HMZD<7EI(C;0S$\C!YX_I6O?ZGH6O.M_<6\RW3*%,<B-+$0
M<?*" Q&>Y_/&*X:3PCXJL()97\.WD2,0/,6%)0 3T 1\GZU9T_P_XQD+VMIH
MVI1K !DM$B*<\Y!<^_0=*RK4Z=2?M$N5VM=-K3>W7K_PZ,X4^5W;N_.VNEMM
M%M\BQJ/C#1;3PVVEV"RO>^85E5;9Q@ C;G)([= 2,5QVHF*"Z25M\[21A$1
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M.H>*-'E:4V][C(^3;"P&??(_SBJ;NK?UT&9'_"-W$UT-/A5!YH:XD;.5B7.
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MKGJ='&9&VKR3T'K51C*3Y4!>;6K]RQ:8'<2Q^4<FB/6KZ*2-TD4,G3Y!4?\
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M"OH']FC[OB+ZP?\ L]?/U?0/[-'W?$7U@_\ 9Z /?J\5_:2_Y%+1_P#K^/\
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M?9KC(5XMO0HPY']:N7\5OXNTB[$XV:WIZF2?RHL)=1Y(\]0!\I4E0_KU[5"
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ML#JNER174:1W*2DJP;.&P.GX5N^$M'U'1]*WSPVZB2430O//LRV"%. >0<\
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MND:>U_J]K;-A5DD 9FX 'N:].\?3VLU_HGA^PDMIHM+M_.F\M]R23-VSTX
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M[_+HQ\,LIA):&VC1?NDR-TIKSO%=0B>*/R2#EXV<X..,^U/NDNI(W@CC$'&
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MQZ5)8D<W]N?#75_+"+<6VH"Z>,G&(W&"1Z\C&*X*O1='MO[$\%Z['/$IFNH
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M*VN^*+.TSLB5O-FD(.(XUY9B>P %7&I*/P_I_DQ6.YT6WE\$^&;>^AD":[J
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MPW^%:EM:F.)$.[S8A@$< CG\LT 3,UM>0S13HJ*40,CC@]>XI+-3 J_94#-
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MT!0))M,8Y7<<FL+4[21+Q[JR"0SQLP\O&(Y1DG##U(Z&H+;Q-; .EW!+:3(
M&4IN '/<=J .Q25/WB.5'$9 (^M<=XFNX)4>-[X0Q-A5BC3+,3GD^GM5]]4%
MS;&XLH)9X,)$LA.Q"?F[GL:6_P!"O5U&,W=G#'<S0^9'*)1,I7@D+CH0,]:
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MXP?W2=#U[4Z#Q5K3LH:]SF6)?]4G0@Y[5G*A!=6#S'%+[$?O?^1XW_8FK?\
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M[AB3\S%&.3[FNQ&KWVX_OS]\_P (]0/2D75K[Y?WY[?PCV]O<UT>WJ=E]_\
MP#M638;_ )^2^Y?YG%O;7$:EG@E51U)0@"O?/V:/N^(OK!_[/7E>J:C=S:5-
M'),64J,C Y^[_C7J?[-!X\1#_KA_[/6].;DKR1X^/PU/#U%&G)M-7U27Y'O]
M>*_M)?\ (I:/_P!?Q_\ 1;5[57BO[27_ "*6C_\ 7\?_ $6U:GGGS6,=S4BK
M%W<XJ*BMJ=50WBGZW_S$T61%;$<S$?A3C':L<F<Y^E5**[ECZ:5O80_\F_\
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M#_(ZZ<7%6;OZGJ7_  B7PNS_ ,CM=C@GF#V_W*/^$2^%O/\ Q6]WQV\DY_\
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M@'K%C_V7_.:S7TKPVOW-9<_\!_\ K5S5%;1H27_+QO[O\CKIXNE%:T8OUO\
MYG1?V9X?S_R%V_[YJ&[T_18K21X-2:695^5,=36'15JE)/XG^'^1<L=2E%I4
((+_P+_,__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
